The introduction of immuno-oncology and, in particular the checkpoint inhibitors, into oncology practice has resulted in a sea change in the way malignancies are treated. Checkpoint inhibitors harness the patient’s own immune system to destroy cancer cells by targeting key pathways involved in the pathogenesis of malignancies. This online activity explains the mechanisms of action of the checkpoint inhibitors, reviews evidence for their efficacy from major clinical trials both as monotherapy and in combination with other agents, and evaluates strategies for mitigating the adverse events associated with checkpoint inhibitor therapy.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Describe the mechanisms of action of immune checkpoint inhibitors in cancer therapy
- Summarize evidence for the roles of checkpoint inhibitors in clinical management of patients with cancer
- Formulate strategies to identify and manage adverse events, toxicities, and adherence challenges associated with checkpoint inhibitors for treatment of cancer
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Heather Greene, MSN, FNP, AOCNP, West Cancer Center, Germantown, Tennessee
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until August 15, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Richard Lindsay, PA-C, MD Anderson Cancer Center, Houston, Texas
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Agios; Astellas Pharma Inc.; Astellas and Pfizer, Inc.; Bristol-Myers Squibb; Celgene Corporation; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co., Inc.
Practicing Clinicians Exchange gratefully acknowledges Miller Medical Communications, LLC, for their contributions as educational partners for this program.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Eaby-Sandy: speakers bureau: AstraZeneca, Helsinn, Merck, Takeda.
Dr Schwartzberg: consultant: Amgen, AstraZeneca, Pfizer.
None of the members of the Planning Committee, CE Alliance staff, Miller Medical Communications staff, or independent reviewer have any relevant relationships to disclose, except Dr Schwartzberg as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 15, 2019
Expiration date: August 15, 2020
© 2019 Practicing Clinicians Exchange. All Rights Reserved. OPCE94719-7A